Abstract
Antibodies have become one of the dominant therapeutic platforms due to their safety, specificity, and efficacy. Owing to their massive potential diversity intrinsic to their structure, the number of possible different molecules that could be generated and analyzed from natural or synthetic systems is almost limitless. However, even with vast improvements in automation, classic antibody generation and analysis systems are severely limited in the number of molecules that can be interrogated during a typical discovery campaign. When one considers more complex target systems, along with the desire to isolate antibodies with very unique characteristics, the chances are very low that these systems will be successful. Next generation sequencing technologies (also referred to as “deep sequencing”) allow for the analysis of single molecules in millions in a very short period of time. By applying these deep sequencing technologies to antibody discovery, we now have the ability to look for very specific molecules with very unique properties and activities, further our understanding of species and strain specific repertoires, and can now begin to use sequence information to identify function. The application of these technologies is opening the door to the discovery of next generation antibody therapeutics.
Keywords: Antibody discovery, biotherapeutic, deep sequencing, diversity, phage display, rodent immunization.
Current Drug Discovery Technologies
Title:Deep Sequencing Approaches to Antibody Discovery
Volume: 11 Issue: 1
Author(s): Michael F. Naso, Jin Lu and Tadas Panavas
Affiliation:
Keywords: Antibody discovery, biotherapeutic, deep sequencing, diversity, phage display, rodent immunization.
Abstract: Antibodies have become one of the dominant therapeutic platforms due to their safety, specificity, and efficacy. Owing to their massive potential diversity intrinsic to their structure, the number of possible different molecules that could be generated and analyzed from natural or synthetic systems is almost limitless. However, even with vast improvements in automation, classic antibody generation and analysis systems are severely limited in the number of molecules that can be interrogated during a typical discovery campaign. When one considers more complex target systems, along with the desire to isolate antibodies with very unique characteristics, the chances are very low that these systems will be successful. Next generation sequencing technologies (also referred to as “deep sequencing”) allow for the analysis of single molecules in millions in a very short period of time. By applying these deep sequencing technologies to antibody discovery, we now have the ability to look for very specific molecules with very unique properties and activities, further our understanding of species and strain specific repertoires, and can now begin to use sequence information to identify function. The application of these technologies is opening the door to the discovery of next generation antibody therapeutics.
Export Options
About this article
Cite this article as:
Naso F. Michael, Lu Jin and Panavas Tadas, Deep Sequencing Approaches to Antibody Discovery, Current Drug Discovery Technologies 2014; 11 (1) . https://dx.doi.org/10.2174/15701638113106660040
DOI https://dx.doi.org/10.2174/15701638113106660040 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of Novel Sesamol Dimers with Unusual Methylenedioxy Ring-Opening Skeleton and Evaluation of Their Antioxidant and Cytotoxic Activities
Current Organic Synthesis Evolution of Novel Non-Steroidal Anti-Inflammatory Drugs with Reduced Gastrointestinal Adverse Effects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthesis and Cytotoxicity Studies on Novel Piperazinylacetamides
Letters in Drug Design & Discovery Response Surface Methodology for Optimization of Ultrasound Assisted Extraction of Swertiamarin from Enicostema littorale Blume
Current Bioactive Compounds Newly Recognized Receptors for Vitamin D Metabolites
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Natural Marine Anti-inflammatory Products
Mini-Reviews in Medicinal Chemistry Structure and Ligand Based Drug Design Strategies in the Development of Novel 5- LOX Inhibitors
Current Medicinal Chemistry Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS
Current Pharmaceutical Biotechnology Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets Effects of Various Processing Methods, Additives and Methanol Extracts on Anti-oxidative Properties of Corn Based Snack Food
Current Nutrition & Food Science The Role of MRI in Treatment Planning for Rectal Cancer - A Review
Current Cancer Therapy Reviews Emerging Vascular Risk Factors in Women: Any Differences from Men?
Current Medicinal Chemistry Applications of Biophysical Tools to Target-Based Discovery of Novel Antibacterial Leads
Current Drug Targets Nanoparticle Enabled Drug Delivery Across the Blood Brain Barrier: in vivo and in vitro Models, Opportunities and Challenges
Current Pharmaceutical Biotechnology Database Construction and Peptide Identification Strategies for Proteogenomic Studies on Sequenced Genomes
Current Topics in Medicinal Chemistry Ultrasound Assisted Synthesis of 2-Substituted Benzofurans via One-Pot and Sequential Method: Their In Vitro Evaluation
Anti-Cancer Agents in Medicinal Chemistry DNA Methylation Markers in Lung Cancer
Current Genomics FRET Enhanced Fluorescent Nanodiamonds
Current Pharmaceutical Biotechnology The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21)
Current Protein & Peptide Science Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect
Current Drug Therapy